{"product_id":"china-point-of-care-testing-poct-market-research-report-2022","title":"China Point-Of-Care Testing (POCT) Market Research Report 2022","description":"\u003cp\u003eChina Point-Of-Care Testing (POCT) Market Research Report 2022\u003c\/p\u003e\n\n\u003cp\u003eMarket Analysis and Insights: China Point-of-Care Testing (POCT) Market\u003c\/p\u003e\n\n\u003cp\u003eDue to the COVID-19 pandemic, the China Point-of-Care Testing (POCT) market size is estimated to be worth US$ 2341 million in 2022 and is forecast to a readjusted size of US$ 4959 million by 2028 with a CAGR of 13.33% during the review period. Fully considering the economic change by this health crisis, Blood Glucose Testing accounting for 43.75% of the Point-of-Care Testing (POCT) China market in 2021, is projected to value US$ 1797 million by 2028, growing at a revised 10.8% CAGR in the forecast period.\u003c\/p\u003e \n\n\u003cp\u003eIn China, the key manufacturers of Point-of-Care Testing (POCT) include Roche, Abbott, LifeScan, Siemens Healthineers, Danaher, Ascensia, Bio-Rad Laboratories, BioMerieux, and ARKRAY, etc. In 2021, the top five players have a share approximately XX% in terms of revenue.\u003c\/p\u003e\n\n\u003cp\u003eChina Point-of-Care Testing (POCT) Scope and Segment\u003c\/p\u003e\n\n\u003cp\u003ePoint-of-Care Testing (POCT) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the China Point-of-Care Testing (POCT) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type, and by Application for the period 2017-2028.\u003c\/p\u003e\n\n\u003cp\u003eSegment by Type\u003c\/p\u003e\n\n\u003cp\u003eBlood Glucose Testing\u003c\/p\u003e\n\n\u003cp\u003eInfectious Diseases Testing\u003c\/p\u003e\n\n\u003cp\u003eCardiac Markers Testing\u003c\/p\u003e\n\n\u003cp\u003eCoagulation Testing\u003c\/p\u003e\n\n\u003cp\u003ePregnancy and Fertility Testing\u003c\/p\u003e\n\n\u003cp\u003eBlood Gas\/Electrolytes Testing\u003c\/p\u003e\n\n\u003cp\u003eUrinalysis Testing\u003c\/p\u003e\n\n\u003cp\u003eOther\u003c\/p\u003e\n\n\u003cp\u003eSegment by Application\u003c\/p\u003e\n\n\u003cp\u003eClinics\u003c\/p\u003e\n\n\u003cp\u003eHospitals\u003c\/p\u003e\n\n\u003cp\u003eLaboratory\u003c\/p\u003e\n\n\u003cp\u003eOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Company\u003c\/p\u003e\n\n\u003cp\u003eRoche\u003c\/p\u003e\n\n\u003cp\u003eAbbott\u003c\/p\u003e\n\n\u003cp\u003eLifeScan\u003c\/p\u003e\n\n\u003cp\u003eSiemens Healthineers\u003c\/p\u003e\n\n\u003cp\u003eDanaher\u003c\/p\u003e\n\n\u003cp\u003eAscensia\u003c\/p\u003e\n\n\u003cp\u003eBioMerieux\u003c\/p\u003e\n\n\u003cp\u003eARKRAY\u003c\/p\u003e\n\n\u003cp\u003eSinocare\u003c\/p\u003e\n\n\u003cp\u003eWondfo\u003c\/p\u003e\n\n\u003cp\u003eYuwell\u003c\/p\u003e\n\n\u003cp\u003eRunbio\u003c\/p\u003e\n\n\u003cp\u003eKHB\u003c\/p\u003e\n\n\u003cp\u003eWuhan Easy Diagnosis\u003c\/p\u003e\n\n\u003cp\u003eJ.H.Bio-Tec\u003c\/p\u003e\n\n\u003cp\u003eGetein Biotech\u003c\/p\u003e\n\n\u003cp\u003eReLIA\u003c\/p\u003e\n\n\u003cp\u003eBIOUHAN\u003c\/p\u003e\n\n\u003cp\u003eBeijing Wantai BioPharm\u003c\/p\u003e\n\n\u003cp\u003eHotgen\u003c\/p\u003e\n\n\u003cp\u003eIntec PRODUCT\u003c\/p\u003e\n\n\u003cp\u003eShenzhen YHLO\u003c\/p\u003e\n\n\u003cp\u003eKang Hua\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 149 Pages \/ MCW16234050","offer_id":47650857713970,"sku":null,"price":4080.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/china-point-of-care-testing-poct-market-research-report-2022","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}